The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC
Abstract Several observational studies suggested that gut microbiome-affecting-medication impairs the effectiveness of immunotherapy in patients with metastatic non-small-cell lung cancer (NSCLC). We postulated that if the effectiveness of immunotherapy is affected by drug-related changes of the mic...
Guardado en:
Autores principales: | M. V. Verschueren, C. M. Cramer - van der Welle, M. Tonn, F. M. N. H. Schramel, B. J. M. Peters, E. M. W. van de Garde |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a0e194b7608d42b8959e5d8b5ea66396 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
por: Christine M. Cramer-van der Welle, et al.
Publicado: (2021) -
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick O, et al.
Publicado: (2021) -
Lung microbiome alterations in NSCLC patients
por: Leliang Zheng, et al.
Publicado: (2021) -
COVID-19 and the Gut Microbiome: More than a Gut Feeling
por: Daniel van der Lelie, et al.
Publicado: (2020) -
Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Jean-Louis Pujol, MD, PhD, et al.
Publicado: (2021)